Cefozopran hydrochloride

Product NameCefozopran hydrochloride
CAS113981-44-5
MFC19H18ClN9O5S2
MW551.98
EINECS1806241-263-5
MOL File113981-44-5.mol

Chemical Properties

storage temp.	under inert gas (nitrogen or Argon) at 2-8°C
Water Solubility	Water : ≥ 52 mg/mL (94.20 mM)

Usage And Synthesis

Antimicrobial activity

Cefazolam hydrochloride is suitable for Staphylococcus, Streptococcus, Enterococcus, Peptostreptococcus, Escherichia coli, Enterobacter, Serratia, Klebsiella, Citrobacter, Proteus, Pseudomonas, Influenza Bacillus, Acinetobacter, Bacteroidetes, septicemia caused by sensitive bacteria to cefazolam hydrochloride, trauma infection, respiratory system, urinary system and abdominal cavity, pelvic purulent inflammation, ophthalmology and ENT inflammation, etc.

Biological Activity

Cefozopran (SCE-2787) hydrochloride is a semi-synthetic, parenteral, fourth-generation cephalosporin. As an antibiotic, it has broad-spectrum antibacterial activity and can inhibit most Gram-negative and Gram-positive bacteria.

in vitro

Cefozopran (SCE-2787) is a fourth-generation cephalosporin that has good activity against gram-positive organisms including methicillin-susceptible staphylococci, enterococci, and viridans group streptococci; and against gram-negative organisms including hemophilus influenza. Moreover, cefozopran has comparatively good activity against enterococci and P. aeruginosa , which are refractory to other cephalosporins.

in vivo

Cefozopran (SCE-2787) (5-80 mg/kg; sc; twice a day for 5 days; four-week-old ICR male mice) is effective against acute respiratory tract infections caused by Kiebsiella pneumonia DT-S. In the model of chronic respiratory tract infection caused by K. pneumoniae 27, Cefozopran (20-80 mg/kg; sc; twice a day for 7 days; five-week-old CBA/J female mice) is as effective as Ceftazidime.